Fig. 2

Cariporide sensitizes resistant breast cancer cells to chemotherapeutic drugs. (a) Cells were treated with a range of cariporide concentrations(3-100 μg/ml) for 24 and 48 h, and the OD value was measured for the CCK8 assay. We chose 6 μg/ml cariporide as the combined-treatment concentration in the follow-up experiments. (b) Cells were treated in the presence or absence of 6 μg/ml cariporide and doxorubicin (1, 5, 50, 100 μg/ml) at the indicated time points and were tested using a CCK8 assay. (c) Cells were treated with different concentrations (0.2, 0.5, 1.2, 30 μg/ml) of paclitaxel for 24 and 48 h and were tested using a CCK8 assay. (d) MCF-7//ADR cells were treated with the combination treatment of cariporide (6 μg/ml) and paclitaxel (0.2, 0.5, 1.2, 30 μg/ml) for 48 h, and cell proliferation was detected using a CCK-8 assay. (e) MCF-7/ADR cells were incubated with 6 μg/ml cariporide for 48 h, NHE1 protein expression was detected by western blot, and (f) NHE1mRNA was confirmed by RT-PCR at 24 h. Cycling conditions were as follows: 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 45 s, with a final extension step of 95 °C for 15 s, 60 °C for 20 min, 95 °C for 15 s, and 60 °C for 15 s